The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent commercialization license to GlaxoSmithKline Intellectual Property Development Ltd (GSK) located at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Document
Prospective Grant of Exclusive Patent Commercialization License: N6, A Novel, Broad, Highly Potent HIV-Specific Antibody
The National Institute of Allergy and Infectious Diseases (NIAID), an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating t...
Legal Citation
Federal Register Citation
Use this for formal legal and research references to the published document.
82 FR 56623
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Prospective Grant of Exclusive Patent Commercialization License: N6, A Novel, Broad, Highly Potent HIV-Specific Antibody,” thefederalregister.org (November 29, 2017), https://thefederalregister.org/documents/2017-25745/prospective-grant-of-exclusive-patent-commercialization-license-n6-a-novel-broad-highly-potent-hiv-specific-antibody.